AstraZeneca gets China nod for Datroway: Can AZN sustain its upward rally?

Traders Union
All News
Stocks
AstraZeneca jumps 3.56% on China approval

Highlights

AstraZeneca received regulatory approval for Datroway in breast cancer in China, opening direct access to a large healthcare market.
The company announced strong late-stage oncology trial results and expanded its research capacity with a $2 billion Summit Therapeutics equity investment and new oncology partnership.
Shares of AstraZeneca are experiencing strong buyer pressure with very high probability of trading between GBX12,090 to GBX12,627 over 2 to 3 days, but overbought conditions suggest potential for short-term pullback.

Regulatory win in China and new deals fuel growth prospects

AstraZeneca has secured regulatory approval in China for Datroway in breast cancer, providing direct access to one of the world's largest healthcare markets and setting the stage for new revenue streams. The company has also announced strong late-stage oncology trial results, which strengthen investor conviction in the commercial potential of its drug pipeline. Completion of a $2 billion equity investment into Summit Therapeutics and the formalization of a joint oncology collaboration further expand its research capacity, while recent partnerships to enhance clinical trial infrastructure in India and ongoing cardiovascular studies highlight a broadening strategic scope.

Bullish bias as buyers dominate but overbought signals emerge

AZN is currently trading above both the MA-20 at GBX12,081 and the MA-50 at GBX12,060, while it remains below the longer-term MA-200 at GBX13,501. The Ichimoku Kijun level, acting as immediate support, stands at GBX12,073. Intraday momentum signals are mixed: RSI, ADX, and the Awesome Oscillator all point to bullish momentum, but Stoch RSI, CCI, and Bull/Bear Power indicate overbought conditions, with MACD remaining neutral. The shares are trading near the day's high and after a negative opening gap, suggesting strong buyer dominance, but overbought oscillator readings and divergence from momentum indicators caution that the rally may be stretched and subject to a short-term pullback.

Upward continuation likely amid constrained volatility band

Over the next 2–3 trading days, AZN is expected to trade within a volatility band of GBX12,090 to GBX12,627. The baseline scenario sees price action remaining inside this range, with a very high probability of upward continuation in the short term. If AZN breaks above the stated resistance, further gains are possible within this corridor; alternatively, a breach of immediate support at the Kijun level could open limited downside risk toward the lower end of the expected range.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca’s share price supported by strong regulatory news from China and a series of oncology partnerships. However, he notes mixed technical momentum and rising overbought signals, which could limit further gains in the immediate term. Base case is for consolidation within GBX12,090 to GBX12,627, with upside possible only if resistance is cleared. "I remain cautious here — until there's a convincing breakout above resistance, this rally looks stretched and susceptible to a pullback."

Earlier, analysts noted that AstraZeneca shares were under sustained pressure, with downside risks dominating despite the company's expansion and pipeline efforts. The latest developments mark a shift in technical posture, with upward momentum prevailing in the short term, but traders should monitor for potential retracement if the shares move below the immediate Kijun support level.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.